Moderate tricuspid regurgitation (TR) management remains controversial. This study evaluated outcomes of conservative management in patients with moderate TR and tricuspid index (TI) <21. Methods: This single-centre retrospective observational study included 66 patients who underwent left-sided valve surgery between April 2018 and December 2025 without concomitant tricuspid valve intervention. Patients with secondary moderate tricuspid regurgitation and a tricuspid annular index <21 were followed clinically and echocardiographically for 12 months. Results: The cohort included 66 patients (mean age, 40.7 ± 12.1 years), comprising 50 MVR (75.8%) and 16 DVR (24.2%) patients. Preoperatively, 33 patients (50%) had atrial fibrillation (AF), with no concomitant ablation. At 12 months, TR regressed to mild in 55 patients (83.3%), while 11 (16.7%) demonstrated non-regression, including 10 with persistent moderate TR and 1 with progression to severe TR. NYHA class II was observed in 60 patients (90.9%), while 6 (9.1%) remained in class III. RVSP showed early postoperative stabilization, maintained throughout follow-up. Conclusion: Non-operative management of moderate TR with TI <21 appears safe during short-term follow-up.
Clinically significant tricuspid regurgitation (TR) affects more than 70 million people worldwide [1], with women experiencing a 4.3-fold higher prevalence than men [2].
Historically, the medical community underemphasized the clinical significance of tricuspid valve function relative to the mitral and aortic valves, assuming that severe TR could be adequately managed with medical therapy alone [3]. However, modern paradigms have shifted significantly. Left uncorrected during left-sided valve surgery, mild-to-moderate functional TR can progress in more than 25% of patients [4]. This progression drives right-sided heart failure, recurrent hospitalizations, and decreased long-term survival, independent of left ventricular ejection fraction (LVEF), RV dimensions, or pulmonary artery pressures [5,6,7].
The institution policy has been to intervene in all patients having moderate TR undergoing left sided valve surgery having annular dilatation ( >40 mm or 21 mm/cm2 ) [8]. This Institutional policy was based on the prevailing international guidelines and resources available in the institution.
The patients who did not undergo concomitant tricuspid valve repair with left sided valve intervention based on the above policy were included in this study. The purpose of this study was to evaluate the clinical and echocardiographic outcomes of these patients.
Patient Selection
We conducted a retrospective analysis of 66 patients who underwent left sided valve surgery between April 2018 and December 2025. Those who did not undergo Tricuspid valve intervention and had secondary moderate TR with indexed tricuspid annular diameter (TAI) < 21 were included in the study.
Patients who had primary Tricuspid regurgitation and patients undergoing additional procedures like concomitant coronary artery bypass grafting (CABG) were excluded.
Clinical and surgical details were retrieved from institutional databases, intraoperative logs, and subsequent outpatient department (OPD) follow-up records. Functional capacity was assessed using the New York Heart Association (NYHA) functional classification via structured patient interviews.
Echocardiographic Evaluation
Transthoracic echocardiography (TTE) was routinely performed preoperatively and at 3, 6, and 12 months postoperatively as per institutional protocol. Key parameters recorded included LVEF, right ventricular systolic pressure (RVSP), and TR severity grade (mild, moderate, or severe). TR severity was quantified semi quantitatively using colour flow mapping (CFM) from the standard apical four-chamber view. The tricuspid annular index was calculated as follows:
TAI = Tricuspid Annular Diameter (mm)/Body Surface Area (m2)
Statistical Analysis
Continuous variables are expressed as mean ± standard deviation (SD), and categorical variables are presented as frequencies and percentages. To account for repeated measures within individual subjects over time, TR severity was dichotomized into "mild" versus “moderate". Temporal changes in TR severity across the 3-, 6-, and 12-month intervals were analysed using Cochran’s Q test and p value < 0.05 was considered statistically significant.
Baseline Characteristics
The final cohort comprised 66 patients with a mean age of 40.7 ± 12.1 years [range 19-68 years]. Mitral valve replacement (MVR) was performed in 50 patients (75.8%) and double valve replacement (DVR) was done in 16 patients (24.2%). Preoperative rhythm analysis revealed an equal distribution in sinus rhythm (n=33) and atrial fibrillation (AF) (n=33). No patient underwent a concomitant ablation procedure.
Postoperative Evolution of Tricuspid Regurgitation
During the study period significant spontaneous regression of TR was observed early and maintained throughout the study period:
Based on the 12-month outcome, two phenotypes were identified: TR regression and TR non regression.
TR regression occurred in 55 patients (83.3%) and TR non regression in 11 patients (16.7%). Of this one patient (1.5%) progressed to severe TR, while 10 patients continued to have moderate TR. [Fig 1]
After 12 months, 60 patients (90.9%) were classified as NYHA functional class II and 6 patients (9.1%) as class III. Echocardiographic assessment showed early postoperative stabilization of RVSP that persisted through the 12-month assessment.
Fig 1: Evolution in severity of Tricuspid Regurgitation over a period of 1 year.
Predictors of TR non regression
The established risk factors like Atrial Fibrillation, Age, Mean Annular Diameter and pulmonary artery pressures were not found to be independent risk factors of TR non regression on univariate analysis.[Table 1, Figure 2 ]
Table -1: Risk factors for non-regression of TR
Fig 2: Univariate odds ratios for TR regression.
For decades, secondary tricuspid regurgitation was considered a passive bystander in left-sided valvular disease, with clinicians anticipating uniform regression following the correction of mitral or aortic lesions [8]. However, contemporary data established that prognostic impact of uncorrected TR, which frequently causes progressive right-sided heart failure and excess mortality [9-11].
Nath et al. demonstrated that moderate-to-severe TR is independently linked to worse mid- and long-term survival compared to mild TR [12].
The 2020 AHA/ACC guidelines on management of patients with valvular heart disease advocate intervention in patients with secondary mild or moderate TR with annular dilatation or having signs of right heart failure [13].
The 2021 ESC/EACTS guidelines on management of patients with valvular heart disease advocate tricuspid intervention in patients with secondary mild or moderate TR with annular dilatation [11].
Our institutional policy was however to intervene in patients with only moderate TR with annular dilatation. The patients having mild TR or moderate TR without annular dilatation did not undergo tricuspid intervention.
Kwak et al evaluated the development of late de novo TR in 335 patients who underwent left-sided valve surgery between 1992 and 1995 with no significant preoperative TR and who completed at least 5 years of Echo follow-up. The study subjects were evaluated over a mean follow-up duration of 11.6 ± 2.1 years. Results indicated that significant late TR developed in 90 patients, representing 26.9% of the cohort. Although univariate analysis showed that late TR was associated with older age, greater left atrial dimension, prior valve surgery, and having undergone mitral valve surgery, multivariate analysis identified preoperative atrial fibrillation as the sole independent predictor of late TR development, carrying an odds ratio of 5.37. Furthermore, patients who developed significant late TR experienced a significantly lower event-free survival rate than those who did not. Our study did not look at this subset of patients [4].
Song et al evaluated the incidence and clinical impact of late significant TR in 638 patients who underwent successful left-sided valve surgery without any concomitant tricuspid repair. Patients included in the study had mild preoperative TR. The mean echocardiographic follow-up of 64 ± 30 months and a mean clinical follow-up of 101 ± 24 months. Results demonstrated an overall incidence of late significant TR of 7.7%. Multivariate analysis revealed that older age, female gender, rheumatic etiology, atrial fibrillation, and the peak pressure gradient of TR at follow-up were independent risk factors for developing late significant TR. Furthermore, the development of late significant TR was associated with adverse clinical outcomes, as these patients exhibited a significantly lower 8-year clinical event-free survival rates. Our study however looked at patients with moderate TR having no annular dilatation [14].
Bolumburu et al. did prospective observational study investigated the progression of TR in a cohort of 1,442 patients presenting with at least moderate TR at baseline. Over a median echocardiographic follow-up duration of 2.3 years, 19% of patients experienced TR progression, 43% remained stable, and 38% exhibited TR regression. The results indicated that older age, lower body mass index, chronic kidney disease, worse NYHA functional class, and right ventricular dilation were independent predictors of TR progression. Furthermore, TR progression correlated with increased chamber dilation, reduced left ventricular ejection fraction, and significantly higher rates of cardiovascular mortality and heart failure hospitalizations. Our study on the contrary found that significant number of patients (83.1%) patient had regression of TR and only 1.5% patients had progression of TR at 1 year follow up. None of the risk factors we investigated were found to be predictors of TR non regression [15].
Kim et al. demonstrated that combining a surgical ablation procedure with left-sided valve operations can significantly mitigate late TR progression by restoring sinus rhythm [16]. However we did not perform any ablation procedure in our cohort.
The 2025 ESC/EACTS guidelines for management of patients with valvular heart disease advocate tricuspid valve intervention in all patients having moderate secondary TR undergoing left sided valve surgery, however our study supports a more conservative approach.
Study Limitations
This study has several limitations that restrict the generalizability of its findings:
An evidence-based approach to treating moderate functional tricuspid regurgitation during left-sided valve surgery is prudent and should be followed. Conservative management is highly effective and reliable when guided by a tricuspid annular index < 21. Utilizing the TAI as a definitive surgical filter helps prevent unnecessary tricuspid interventions while maintaining excellent short-term clinical safety and promoting spontaneous valvular regression.